Aprogenex and Centocor in development agreement:
This article was originally published in Clinica
Executive Summary
Biotech company Centocor has struck a product development and licence agreement with Aprogenex for the latter's DNA Probe in situ hybridisation technology. Centocor will be responsible for development, as well as regulatory approvals and marketing. Aprogenex, which is based in Houston, Texas, will receive an upfront licensing fee, milestone payments and royalties on products utilised by Centocor. Aprogenex' testing systems are based on its RIGHTechnology, which can be used in genetics, oncology, virology and microbiology.